F. Salgado Castro (Santiago De Compostela, Spain), M. Kraft (New York, United States)
Inter-observer agreement on biological treatment decision for severe asthma.
M. Boulay (Quebec, Canada), R. Beaulé (Quebec, Canada), L. Boulet (Quebec, Canada), K. Godbout (Quebec, Canada), D. Price (Singapore, Singapore), A. Côté (Quebec, Canada)
|   |
A single-centre retrospective review of asthma and pregnancy outcomes after exposure to monoclonal antibody therapy for severe asthma
H. Joplin (Liverpool (Merseyside), United Kingdom), A. Nuttall (Liverpool (Merseyside), United Kingdom), S. Zaidi (Liverpool (Merseyside), United Kingdom), G. Jones (Liverpool (Merseyside), United Kingdom), L. Chishimba (Liverpool (Merseyside), United Kingdom), H. Burhan (Liverpool (Merseyside), United Kingdom)
| |
Perceptions on home-administration of biologics in severe asthma: an international qualitative study.
B. Flokstra - De Blok (Groningen, Netherlands), J. Kocks (Groningen, Netherlands), H. Wouters (Groningen, Netherlands), C. Arling (Groningen, Netherlands), J. Chatelier (Melbourne, Australia), J. Douglass (Melbourne, Australia), L. Heaney (Belfast, United Kingdom), J. Holmes (Belfast, United Kingdom), M. Humbert (Paris, France), M. Kolanowski (Michigan, United States), J. Landsman (Groningen, Netherlands), N. Lugogo (Michigan, United States), A. Malpass (Bristol , United Kingdom), J. Meijer (Groningen, Netherlands), B. Metz (Groningen, Netherlands), B. De Mul (Groningen, Netherlands), F. Postma (Groningen, Netherlands), M. Leving (Groningen, Netherlands)
| |
Real-world effectiveness of anti-IL-5/5R therapy in severe eosinophilic asthma with comorbid bronchiectasis
S. van Nederveen-Bendien (The Hague, Netherlands), H. Kroes (Leeuwarden, Netherlands), A. Maitland- Van Der Zee (Amsterdam, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands)
| |
RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: evaluating the multiple components of response
M. Kallieri (Chaidari, Greece), E. Zervas (Athens, Greece), E. Fouka (Thessaloniki, Greece), K. Porpodis (Thessaloniki, Greece), M. Hadji Mitrova (Thessaloniki, Greece), E. Tzortzaki (Heraklion, Greece), M. Makris (Chaidari, Greece), M. Ntakoula (Chaidari, Greece), A. Papaioannou (Chaidari, Greece), P. Lyberopoulos (Chaidari, Greece), K. Dimakou (Athens, Greece), S. Koukidou (Athens, Greece), S. Ampelioti (Athens, Greece), A. Papaporfyriou (Athens, Greece), K. Katsoulis (Thessaloniki, Greece), M. Kipourou (Thessaloniki, Greece), N. Rovina (Athens, Greece), K. Antoniou (Heraklion, Greece), S. Vittorakis (Chania, Greece), P. Bakakos (Athens, Greece), P. Steiropoulos (Alexandroupolis, Greece), K. Markopoulou (Thessaloniki, Greece), P. Avarlis (Kalamata, Greece), ?. Papanikolaou (Corfu, Greece), M. Markatos (Chania, Greece), E. Gaki (Trikala, Greece), K. Samitas (Athens, Greece), K. Glynos (Athens, Greece), S. Papiris (Chaidari, Greece), D. Papakosta (Thessaloniki, Greece), N. Tzanakis (Heraklion, Greece), M. Gaga (Athens, Greece), K. Kostikas (Ioannina, Greece), S. Loukides (Chaidari, Greece)
| |
Real-world effectiveness (RWE) of dupilumab in reducing healthcare resource utilization among moderate-to-severe asthma patients
A. Pawar (Cambridge, MA, United States), M. Blaiss (Augusta, GA, United States), B. Modena (La Jolla, CA, United States), A. Khan (Chilly-Mazarin, France), L. De Prado Gómez (Reading, United Kingdom), Y. Zhang (Tarrytown, NY, United States), S. Siddiqui (Tarrytown, NY, United States), J. Jacob-Nara (Bridgewater, NJ, United States), L. De Prado Gomez (Reading, United Kingdom)
| |
Real-life experience with biologic therapies in severe uncontrolled asthma
M. Saad (Milano, Italy), F. Mandurino Mirizzi (Milano, Italy), G. Fuccia (Milano, Italy), A. Zuffi (Milano, Italy), E. Maratta (Milano, Italy), L. Milani (Milano, Italy), J. Signorello (Milano, Italy), D. Radovanovic (Milano, Italy), P. Santus (Milano, Italy)
| |
Biologic therapies could prevent lung function decline in severe asthma: a 3 years real life observational study
N. Bougard (Liège, Belgium), F. Schleich (Liège, Belgium), S. Graff (Liège, Belgium), A. Frix (Liège, Belgium), V. Paulus (Liège, Belgium), F. Guissard (Liège, Belgium), R. Louis (Liège, Belgium)
| |
The experience of dual biologic therapy in patients with eosinophilic asthma and autoimmune diseases
A. Matthaiou (Heraklion, Greece), N. Bizymi (Heraklion, Greece), L. Ettronier (Montpellier, France), E. Bibaki (Heraklion, Greece), J. Morel (Montpellier, France), N. Tzanakis (Heraklion, Greece), A. Bourdin (Montpellier, France), K. Antoniou (Heraklion, Greece)
| |
Impact of co-existing chronic rhinosinusitis on the effect of biological therapy in severe asthma - Danish nationwide cohort study
J. Bruun (Copenhagen, Denmark), S. Hansen (Copenhagen, Denmark), C. Lajer (Greve, Denmark), T. Ingebrigtsen (Gentofte, Denmark), C. Ulrik (Hvidovre, Denmark), A. Bjerrum (Aarhus, Denmark), A. Von Bülow (Copenhagen, Denmark), C. Johnsen (Gentofte, Denmark), O. Hilberg (Vejle, Denmark), S. Johansson (Odense, Denmark), K. Assing (Aalborg, Denmark), L. Rasmussen (Gentofte, Denmark), K. Håkansson (Hvidovre, Denmark), J. Schmid (Aarhus, Denmark), M. Søndergaard (Copenhagen, Denmark), L. Dongo (Roskilde, Denmark), C. Porsbjerg (Copenhagen, Denmark)
| |
Severe asthma in obese patients: what to expect with Mepolizumab?
A. Da Cunha Fonseca (Vila Nova de Gaia, Portugal), D. Machado (Vila Nova de Gaia, Portugal), I. Pascoal (Vila Nova de Gaia, Portugal), I. Franco (Vila Nova de Gaia, Portugal), R. Lima (Vila Nova de Gaia, Portugal)
| |
Decision outcomes following referral to a tertiary severe asthma service for MAb therapy.
A. Nuttall (Liverpool, United Kingdom), H. Joplin (Liverpool, United Kingdom), C. Lowe (Liverpool, United Kingdom), G. Jones (Liverpool, United Kingdom), S. Zaidi (Liverpool, United Kingdom), H. Burhan (Liverpool, United Kingdom), L. Chishimba (Liverpool, United Kingdom)
| |
Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
A. Frix (Liege, Belgium), L. Heaney (Belfast, United Kingdom), B. Dahlén (Stockholm, Sweden), F. Mihaltan (Bucharest, Romania), S. Sergejeva (Tartu, Estonia), D. Doberer (Vienna, Austria), S. Popovic-Grle (Zagreb, Croatia), V. Sedlak (Hradec Kralove, Czech Republic), L. Lehtimäki (Tampere, Finland), A. Bourdin (Montpellier, France), S. Korn (Mainz, Germany), E. Zervas (Athens, Greece), Z. Csoma (Budapest, Hungary), D. Lúðvíksdóttir (Reykjavik, Iceland), M. Butler (Dublin, Ireland), G. Canonica (Milan, Italy), I. Grisle (Riga, Latvia), K. Bieksiene (Kaunas, Lithuania), A. Ten Brinke (Leeuwarden, Netherlands), P. Kuna (Lodz, Poland), C. Chaves Loureiro (Coimbra, Portugal), N. Nenasheva (Moscow, Russian Federation), Z. Lazic (Kragujevac, Republic of Serbia), S. Škrgat (Golnik, Slovenia), D. Ramos-Barbon (Coruna, Spain), J. Leuppi (Basel, Switzerland), B. Gemicioglu (Istanbul, Turkey), A. Bossios (Stockholm, Sweden), C. Porsbjerg (Copenhagen, Denmark), E. Bel (Amsterdam, Netherlands), R. Djukanovic (Southampton, United Kingdom), R. Louis (Liège, Belgium)
| |
Real life benralizumab effectiveness in patients with severe eosinophilic asthma after a 24 month observation
G. Lo Muzio (Roma (RM), Italy), O. Calò (Roma (RM), Italy), C. Cisternino (Roma (RM), Italy), P. Scarano (Roma (RM), Italy), A. Sanna (Roma (RM), Italy), F. De Filippis (Roma (RM), Italy), A. Steffanina (Roma (RM), Italy), M. Leporini (Roma (RM), Italy), P. Palange (Roma (RM), Italy), E. Graziani (Roma (RM), Italy)
| |
Impact of biological therapies in lung function in patients with severe asthma
A. Menéndez-Lobo (Granada, Spain), S. Rojo-Tolosa (Granada, Spain), J. Sánchez-Martínez (Granada, Spain), C. Pérez-Ramírez (Granada, Spain), G. Jiménez-Gálvez (Granada, Spain), A. Jiménez-Morales (Granada, Spain), C. Morales-García (Granada, Spain)
| |
Burden of severe asthma by biologic use and eligibility: an analysis of the International Severe Asthma Registry
T. Le (Gaithersburg, United States), C. Erhard (Cambridge, United Kingdom), D. Price (Aberdeen, United Kingdom), E. Maslova (Cambridge, United Kingdom), B. Cook (Gaithersburg, United States), A. Quinton (Cambridge, United Kingdom), R. Katial (Gaithersburg, United States), G. Christoff (Sofia, Bulgaria), L. Perez-De-Llano (Lugo, Spain), V. Carter (Cambridge, United Kingdom), T. Tran (Gaithersburg, United States), T. Tran (Gaithersburg, United States)
| |
Therapeutic approach with mepolizumab (anti-IL-5) in a series of patients with eosinophilic granulomatosis with polyangiitis
N. Bizymi (Heraklion, Greece), A. Matthaiou (Heraklion, Greece), G. Stathakis (Heraklion, Greece), S. Viziriannaki (Heraklion, Greece), E. Bibaki (Heraklion, Greece), N. Tzanakis (Heraklion, Greece), K. Antoniou (Heraklion, Greece)
| |
Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma – “first initiators” and “switchers”
S. Hashimoto (Amsterdam, Netherlands), J. Kroes (Leeuwarden, Netherlands), K. Eger (Amsterdam, Netherlands), P. Mau-Asam (Amsterdam, Netherlands), H. Hofstee (Leiden, Netherlands), S. Bendien (The Hague, Netherlands), G. Braunstahl (Rotterdam, Netherlands), M. Broeders (’s-Hertogenbosch, Netherlands), L. Imming (Enschede, Netherlands), B. Langeveld (Deventer , Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands), K. Oud (Ede, Netherlands), K. Patberg (Zwolle, Netherlands), F. Smeenk (Eindhoven, Netherlands), E. Romme (Arnhem, Netherlands), M. Van Bezouw (Amsterdam, Netherlands), M. Van De Ven (Arnhem, Netherlands), A. Van Veen (Nijmegen, Netherlands), E. Van Velzen (Amersfoort, Netherlands), I. Van Veen (Enschede, Netherlands), E. Weersink (Amsterdam, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), J. Sont (Leiden, Netherlands), E. Bel (Amsterdam, Netherlands), R. Team (Amsterdam, Netherlands)
| |
Mepolizumab therapy in severe asthma – a study of long term efficacy and safety
C. Reilly (Birmingham (West Midlands), United Kingdom), R. Anandavelu (Birmingham (West Midlands), United Kingdom), J. Marsh (Birmingham (West Midlands), United Kingdom), J. Sullivan (Birmingham (West Midlands), United Kingdom), F. O'Riordran (Birmingham (West Midlands), United Kingdom), S. Cotterill (Birmingham (West Midlands), United Kingdom), L. White (Birmingham (West Midlands), United Kingdom), A. Mansur (Birmingham (West Midlands), United Kingdom)
| |
Dupilumab leads to sustained improvement of asthma control in real-life severe asthmatics.
A. Renner (Wien, Austria), K. Marth (Wien, Austria), K. Patocka (Wien, Austria), M. Idzko (Wien, Austria), W. Pohl (Wien, Austria)
| |